Stocks
Axsome Therapeutics Financial Statements (AXSM) |
||||||||||
| Axsome Therapeuticssmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2021 | 01.03.2022 | 31.12.2022 | 28.02.2023 | 23.02.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 50.0 | 270.6 | 338.5 | |||
| Operating Income, bln rub | -99.1 | -124.7 | -179.8 | -176.5 | -231.8 | -307.5 | ||||
| EBITDA, bln rub | ? | -99.1 | -123.6 | -179.8 | -174.2 | -225.0 | -302.6 | |||
| Net profit, bln rub | ? | -105.4 | -134.9 | -187.1 | -197.8 | -239.2 | -311.0 | |||
| OCF, bln rub | ? | -78.5 | -108.2 | -116.5 | -145.1 | -132.6 | ||||
| CAPEX, bln rub | ? | 0.046 | 0.308 | 0.702 | 0.582 | 0.307 | ||||
| FCF, bln rub | ? | -78.5 | -108.5 | -117.2 | -145.7 | -132.6 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 99.1 | 124.7 | 229.8 | 221.3 | 476.4 | 620.0 | ||||
| Cost of production, bln rub | 0.078 | 1.16 | 5.20 | 5.20 | 26.1 | 32.0 | ||||
| R&D, bln rub | 70.2 | 58.1 | 57.9 | 57.9 | 97.9 | 162.6 | ||||
| Interest expenses, bln rub | 2.57 | 5.70 | 7.33 | 7.33 | 6.45 | 5.06 | ||||
| Assets, bln rub | 186.1 | -338.4 | 331.5 | 331.5 | 588.2 | 561.5 | ||||
| Net Assets, bln rub | ? | -278.8 | -409.2 | 109.6 | 109.6 | 191.0 | 92.9 | |||
| Debt, bln rub | 50.1 | 49.7 | 94.7 | 94.7 | 186.4 | 191.0 | ||||
| Cash, bln rub | 183.9 | 86.5 | 0.000 | 200.8 | 386.2 | 327.3 | ||||
| Net debt, bln rub | -133.8 | -36.8 | 94.7 | -106.2 | -199.8 | -136.3 | ||||
| Ordinary share price, rub | 81.5 | 37.8 | 77.1 | 77.1 | 79.6 | 64.4 | ||||
| Number of ordinary shares, mln | 37.2 | 37.6 | 40.7 | 40.7 | 45.4 | 48.1 | ||||
| Market cap, bln rub | 3 031 | 1 421 | 3 136 | 3 136 | 3 615 | 3 101 | ||||
| EV, bln rub | ? | 2 897 | 1 384 | 3 230 | 3 030 | 3 416 | 2 965 | |||
| Book value, bln rub | -279 | -409 | 40 | 40 | 126 | 32 | ||||
| EPS, rub | ? | -2.83 | -3.59 | -4.60 | -4.86 | -5.27 | -6.46 | |||
| FCF/share, rub | -2.11 | -2.89 | 0.00 | -2.88 | -3.21 | -2.75 | ||||
| BV/share, rub | -7.49 | -10.9 | 0.97 | 0.97 | 2.77 | 0.67 | ||||
| EBITDA margin, % | ? | -348.2% | -83.1% | -89.4% | ||||||
| Net margin, % | ? | -395.2% | -88.4% | -91.9% | ||||||
| FCF yield, % | ? | -2.59% | -7.64% | 0.00% | -3.74% | -4.03% | -4.28% | |||
| ROE, % | ? | 37.8% | 33.0% | -170.8% | -180.5% | -125.3% | -334.7% | |||
| ROA, % | ? | -56.6% | 39.9% | -56.5% | -59.7% | -40.7% | -55.4% | |||
| P/E | ? | -28.8 | -10.5 | -16.8 | -15.9 | -15.1 | -9.97 | |||
| P/FCF | -38.6 | -13.1 | -26.8 | -24.8 | -23.4 | |||||
| P/S | ? | 62.7 | 13.4 | 9.16 | ||||||
| P/BV | ? | -10.9 | -3.47 | 79.2 | 79.2 | 28.8 | 95.8 | |||
| EV/EBITDA | ? | -29.2 | -11.2 | -18.0 | -17.4 | -15.2 | -9.80 | |||
| Debt/EBITDA | 1.35 | 0.30 | -0.53 | 0.61 | 0.89 | 0.45 | ||||
| R&D/CAPEX, % | 153 068% | 18 879% | 8 253% | 16 829% | 52 975% | |||||
| CAPEX/Revenue, % | 1.40% | 0.22% | 0.09% | |||||||
| Axsome Therapeutics shareholders | ||||||||||
